U.S. SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549
                                 FORM 10-QSB

Quarterly  Report Under  Section 13 or 15(d) of the  Securities  Exchange Act of
1934 for the Quarterly Period Ended October 31, 2001

Commission file number 000-29179
                       ---------

                          LANIPRIN LIFE SCIENCES, INC.
                          ----------------------------
        (Exact name of small business issuer as specified in its charter)

       Colorado                                              84-1493154
       --------                                              ----------
(State or other jurisdiction of                     (I.R.S. Identification No.)
Employer incorporation or organization)

            1900 South Ocean Blvd., Suite 5E, Pompano Beach, FL       33034
          -------------------------------------------------------------------
               (Address of principal executive offices)             (Zip Code)

                                  303-979-3224
                                  ------------
                           (Issuer's telephone number)

         Brass Incorporated, 7899 West Frost Drive, Littleton, CO 80128
         --------------------------------------------------------------
              (Former name, former address and former fiscal year,
                          if changed since last report)

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days.  Yes  X       No
                                                               ---        ---

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date.

As of October 31, 2001,  6,230,000  shares of common stock,  no par value,  were
outstanding.

<PAGE>
                                      INDEX


                                                                           Page
                                                                           ----
PART I--FINANCIAL INFORMATION

     Item 1.  Financial Statements

     Condensed balance sheet - October 31, 2001 (Unaudited)                  3

     Condensed statements of operations (Unaudited) - Three and six
            months ended October 31, 2001 and 2000 and April 9, 1998
       (inception) through October 31, 2001                                  4

     Condensed statements of cash flows (Unaudited) - Six months ended
       October 31, 2001 and 2000 and April 9, 1998 (inception) through
       October 31, 2001                                                      5

     Notes to condensed financial statements (Unaudited)                     6

     Item 2.  Plan of operation                                              9

PART II--OTHER INFORMATION                                                   9

     Item 1.  Legal Proceedings
     Item 2.  Changes in Securities
     Item 3.  Defaults Upon Senior Securities
     Item 4.  Submission of Matters to a Vote of Security Holders
     Item 5.  Other Information
     Item 6.  Exhibits and Reports on Form 8-K

     Signatures                                                             10


                                        2
<PAGE>


                          LANIPRIN LIFE SCIENCES, INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                             Condensed Balance Sheet

                                October 31, 2001
                                   (Unaudited)

                                                      Total assets     $   --
                                                                       ========

Liabilities and Shareholders' Deficit
Liabilities:
   Accounts payable and accrued liabilities .......................    $  1,595
   Indebtedness to related parties (Note B) .......................       2,043
                                                                       --------
                                                 Total liabilities        3,638
                                                                       --------


Shareholders' deficit:
   Common stock ...................................................       7,673
   Additional paid-in capital .....................................       4,300
   Deficit Accumulated during the development stage ...............     (15,611)
                                                                       --------
                                       Total shareholders' deficit       (3,638)
                                                                       --------

                       Total liabilities and shareholders' deficit     $   --
                                                                       ========

            See accompanying notes to condensed financial statements

                                        3
<PAGE>

<TABLE>

                          LANIPRIN LIFE SCIENCES, INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                       Condensed Statements of Operations
                                   (Unaudited)
<CAPTION>



                                                                                                         April 9, 1998
                                                 Three Months Ended              Six Months Ended         (inception)
                                                     October 31,                    October 31,             through
                                              --------------------------    --------------------------    October 31,
                                                 2001           2000           2001           2000            2001
                                              -----------    -----------    -----------    -----------    -----------
<S>                                           <C>            <C>            <C>            <C>            <C>
Operating expenses:
   Stock-based compensation (Note B):
      Organizational costs ................   $      --      $      --      $      --      $      --      $       500
   General and administrative .............         1,138            736          2,749          1,809         10,917
   Contributed rent (Note B) ..............           300            300            600            600          4,300
                                              -----------    -----------    -----------    -----------    -----------
                   Total operating expenses         1,438          1,036          3,349          2,409         15,717
                                              -----------    -----------    -----------    -----------    -----------
                             Operating loss        (1,438)        (1,036)        (3,349)        (2,409)       (15,717)

Interest income ...........................          --             --             --             --              106
                                              -----------    -----------    -----------    -----------    -----------
                   Loss before income taxes        (1,438)        (1,036)        (3,349)        (2,409)       (15,611)

Income taxes ..............................          --             --             --             --             --
                                              -----------    -----------    -----------    -----------    -----------

                                   Net loss   $    (1,438)   $    (1,036)   $    (3,349)   $    (2,409)   $   (15,611)
                                              ===========    ===========    ===========    ===========    ===========


Basic and diluted (loss) per common share..   $ *             $*             $*             $*
                                              ===========    ===========    ===========    ===========
Basic and diluted weighted average common
   shares outstanding .....................     6,230,000      1,230,000      5,813,334      1,230,000
                                              ===========    ===========    ===========    ===========
</TABLE>


* Less than $.01 per share

            See accompanying notes to condensed financial statements

                                        4
<PAGE>

<TABLE>
                          LANIPRIN LIFE SCIENCES, INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                       Condensed Statements of Cash Flows
                                   (Unaudited)
<CAPTION>


                                                                               April 9, 1998
                                                           Six Months Ended     (inception)
                                                              October 31,         through
                                                          ------------------    October 31,
                                                           2001       2000         2001
                                                          -------    -------      -------

<S>                                                       <C>        <C>          <C>
                  Net cash used in operating activities   $(2,904)   $(1,658)     $(9,216)
                                                          -------    -------      -------

Cash flows from financing activities:
  Advances from affiliate (Note B) ....................     2,904      1,616        7,043
  Repayment of advances from affiliate (Note B) .......    (5,000)      --         (5,000)
  Sale of common stock ................................     5,000       --          7,300
  Offering costs incurred .............................      --         --           (127)
                                                          -------    -------      -------
              Net cash provided by financing activities     2,904      1,616        9,216
                                                          -------    -------      -------

Change in cash ........................................      --          (42)        --
Cash, beginning of period .............................      --          537         --
                                                          -------    -------      -------

                                    Cash, end of period   $  --      $   495      $  --
                                                          =======    =======      =======

Supplemental  disclosure of cash flow  information:
    Cash paid during the period for:
     Interest .........................................   $  --      $  --        $  --
                                                          =======    =======      =======
     Income taxes .....................................   $  --      $  --        $  --
                                                          =======    =======      =======
</TABLE>

            See accompanying notes to condensed financial statements


                                        5
<PAGE>

                           LANIPRIN LIFE SCIENCES INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                     Notes to Condensed Financial Statements
                                   (Unaudited)

Note A: Basis of Presentation

The financial  statements  presented herein have been prepared by the Company in
accordance with the accounting policies in its audited financial  statements for
the year ended  April 30, 2001 as filed in its Form 10-KSB and should be read in
conjunction with the notes thereto. The Company entered the development stage in
accordance  with Statement of Financial  Accounting  Standard  ("SFAS") No. 7 on
April 9, 1998 and its purpose is to evaluate,  structure,  and complete a merger
with, or acquisition of, a privately owned corporation.

In the  opinion  of  management,  all  adjustments  (consisting  only of  normal
recurring  adjustments)  which are necessary to provide a fair  presentation  of
operating  results for the interim periods presented have been made. The results
of operations  for the period  presented are not  necessarily  indicative of the
results to be expected for the year.

Interim financial data presented herein are unaudited.

Note B: Related Party Transactions

Corporate  Management  Services  ("CMS")  organized  the Company in exchange for
1,000,000  shares of the Company's  common stock. The common stock was valued at
$500 by the Company's Board of Directors.

CMS provided  office space at no charge to the Company,  on an as needed  basis,
from  inception  through May 15, 2001.  Office space was provided by  management
following  the  change in control  on May 15,  2001 (see Note D). The  Company's
Board of Directors valued the contributed office space at approximately $100 per
month,  based on  prevailing  local market  rates.  The  accompanying  financial
statements  include a charge to rent expense and a credit to paid-in  capital of
$600, $600, and $4,300, respectively,  for the six months ended October 31, 2001
and 2000,  and the period  from April 8, 1998  (inception)  through  October 31,
2001.

At April 30, 2001 the Company owed CMS $4,139 for certain  legal and  accounting
expenses  paid by CMS on behalf of the  Company.  During  the six  months  ended
October 31, 2001 CMS paid an additional $2,904 in legal, accounting, and general
and administrative  expenses on behalf of the Company.  In May 2001, the Company
repaid CMS $5,000 with proceeds from the sale of its equity securities (see Note
D). As of October 31, 2001, the balance owed CMS was $2,043.

Note C: Income Taxes

The Company  records its income taxes in accordance  with Statement of Financial
Accounting Standard No. 109, "Accounting for Income Taxes". The Company incurred
net  operating  losses  during  the  periods  shown on the  condensed  financial
statements  resulting  in a deferred  tax asset,  which was fully  allowed  for,
therefore the net benefit and expense result in $-0- income taxes.

                                        6
<PAGE>


                           LANIPRIN LIFE SCIENCES INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                     Notes to Condensed Financial Statements
                                   (Unaudited)

Note D: Change in control

On May 15, 2001, the Company completed a private offering for 1,000,000 units of
the  Company's  equity  securities.  Each  unit  consisted  of 5  shares  of the
Company's  common  stock,  one Class "A" warrant,  one Class "B" warrant and one
Class "C"  warrant.  Units  were sold at $.005  per unit for gross  proceeds  of
$5,000.

Class "A" warrants allow  investors to purchase common stock at $2.00 per share;
Class "B" warrants allow  investors to purchase common stock at $3.00 per share;
and Class "C" warrants  allow  investors  to purchase  common stock at $4.00 per
share.  The warrants are  exercisable  over a three-year  period.  Following the
offering, the Company's issued and outstanding common stock totaled 6,230,000.

The sale of 5,000,000 shares of the Company's common stock, resulted in a change
in control of the Company.

Note E: Reverse acquisition

On June 4, 2001, the Company  entered into a Share Exchange  Agreement with NXI.
This transaction  closed on November 12, 2001. Under the terms of the Agreement,
the Company issued  12,021,500 shares of its common stock to the shareholders of
NXI in exchange for all of the issued and outstanding stock of NXI.

The  Company's  new  business  plan is to enter the  pharmaceutical  and  health
products industry through a reverse merger with Nutrigo Xchange, Inc. ("NXI"), a
Delaware corporation.  NXI plans to develop several over-the-counter  medication
products and an affordable prescription service.

In  anticipation  of the closing of the  Agreement,  the Company's  shareholders
approved the following:

(1)  Name change:
     -----------
     On June 21, 2001, the  shareholders of the Company approved an amendment to
     the  Articles  of  Incorporation  to change the  Company's  name from Brass
     Incorporated to Laniprin Life Sciences, Inc.

(2)  Authorized common stock:
     -----------------------
     On June 21, 2001, the  shareholders of the Company approved an amendment to
     the Articles of Incorporation  to increase the number of authorized  common
     shares from 20,000,000 to 50,000,000.

                                        7
<PAGE>


                           LANIPRIN LIFE SCIENCES INC.
                          (formerly Brass Incorporated)
                          (A Development Stage Company)

                     Notes to Condensed Financial Statements
                                   (Unaudited)

(3)  Stock Option Plan:
     -----------------
     On June 21, 2001, the  shareholders  of the Company  approved the Company's
     2001 Stock  Option Plan.  The Company has  authorized  5,000,000  shares of
     common  stock to be  available  for the  Plan.  The Plan  provides  for the
     granting of incentive  options to employees and  non-qualifying  options to
     non-employees.  No options were granted as of October 31, 2001.  The option
     price,  number of shares and grant date are determined at the discretion of
     the  Company's  Board of Directors of a committee  designated by the Board.
     The exercise price of each incentive  option granted to employees shall not
     be less than 100 percent of the market price of the Company's  stock on the
     date of grant. The exercise price of each non-qualifying  option granted to
     non-employees  shall not be less than 85 percent of the market price of the
     Company's  stock  on the  date  of  grant.  Options  under  this  plan  are
     exercisable for a period not to exceed ten years from the date of grant.


                                        8
<PAGE>

Part I--Item 2. Plan of Operation

The Company's plan of operation has been to seek out, investigate,  and pursue a
merger,  acquisition,  or other business combination with an entity desiring the
perceived  benefits  offered by the Company as a result of its having a class of
securities  registered  under the Exchange Act. There have been no revenues from
operations  since  formation.  The  Company has no full time  employees,  incurs
nominal  rent and  administrative  expenses of $100 per month,  and has no other
recurring operational expenses except professional fees incurred as necessary.

The Company identified a suitable target entity for a business
combination,  and management has entered into a share exchange  agreement  dated
June 4, 2001 with Nutrigo  Xchange,  Inc. The share exchange  agreement has been
approved by the  shareholders  and the  transaction  was closed on November  12,
2001.  The  Company's  business plan is to enter the  pharmaceutical  and health
products industry with the reverse merger with Nutrigo Xchange,  Inc. ("NXI"), a
Delaware corporation.  NXI plans to develop several over-the-counter  medication
products and an affordable prescription service.

Consummating this business opportunity is complex and risky due to the
Company's limited  financial  resources,  the speculative  nature of operations,
management's  limited time  commitment  to the Company,  management's  potential
conflicts of interest,  the burdens of being a reporting company, lack of market
research, and competition in the marketplace.

Part II--Other Information

Items 1 through 3

None

Item 4. Submission of Matters to a Vote of Security Holders

On July 25, 2001 the  shareholders  of the company  approved the share  exchange
agreement dated June 4, 2001 with Nutrigo Xchange, Inc. This transaction has not
closed as of the date of this  filing.  Under the  terms of the  Agreement,  the
Company will issue 12,021,500  shares of its common stock to the shareholders of
Nutrigo Xchange, Inc. in exchange for all of the issued and outstanding stock of
Nutrigo Xchange, Inc. Closing this Agreement would result in a change in control
of the Company.

On July 25, 2001, the  shareholders of the Company  approved an amendment to the
Articles of Incorporation  to change the Company's name from Brass  Incorporated
to Laniprin Life Sciences, Inc.

On July 25, 2001, the  shareholders of the Company  approved an amendment to the
Articles of  Incorporation  to increase the number of  authorized  common shares
from 20,000,000 to 50,000,000.

                                    9
<PAGE>


On July 25, 2001, the  shareholders  of the Company  approved the Company's 2001
Stock Option Plan. The Company has authorized  5,000,000  shares of common stock
to be available for the Plan. No options were granted as of July 31,2001.

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

(a)  Exhibits

       None

(b)  Reports on Form 8-K

On November 12, 2001 the Company closed on the  Acquisition  of Nutrigo  Xchange
Inc.  On July 25,  2001 the  shareholders  of the  company  approved  the  share
exchange  agreement dated June 4, 2001 with Nutrigo Xchange,  Inc. The Company's
business  plan is to enter  the  pharmaceutical  and  health  products  industry
through the  acquisition of Nutrigo  Xchange,  Inc. The Company plans to develop
several  over-the-counter  medication  products and an  affordable  prescription
service.

Under the terms of the Agreement,  the Company is issuing  12,021,500  shares of
its common stock to the  shareholders of Nutrigo  Xchange,  Inc. in exchange for
all of the issued and outstanding stock of Nutrigo Xchange, Inc.





                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

                                    Laniprin Life Sciences, Inc.



Date:  December 19, 2001            By:  /s/ Steven Zeldin
                                         ---------------------
                                         Steven Zeldin, President

                                    10